E-ISSN 2602-3164
EJMI. 2021; 5(2): 225-231 | DOI: 10.14744/ejmi.2021.21203

Could Systemic İnflammation-Based Prognostic Scores Predict The Clinical Outcome in Patients with Breast Cancer Treated with Everolimus Plus Exemestane?

Emir Celik1, Nilay Sengul Samanci1, Mehmet Karadag2, Nebi Serkan Demirci1, Fuat Hulusi Demirelli1
1Department of Medical Oncology, Faculity of Cerrahpasa Medicine, Istanbul University, Istanbul, Turkey, 2Department of Biostatistics, Faculty of Medicine, Hatay Mustafa Kemal University, Hatay, Turkey

Objectives: No study to clarify which inflammation score could best reflect survival in a cohort of metastatic breast cancer (mBC) patients who received everolimus plus exemestane. Methods: The impact of neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR), systemic immune-inflammation index (SII), and prognostic nutritional index (PNI) on PFS and OS was evaluated. Results: A total of 80 mBC patients were included. Median PFS was 8.9 months and median overall survival (OS) was 31.8 months. We found that there was no significant difference between NLR, PLR, SII, and PNI groups for median PFS and OS. Conclusion: Inflammation-based prognostic scores were not correlated with prognosis in patients with mBC who had been treated with everolimus plus exemestane. Keywords: Everolimus; breast cancer; systemic inflammation-based prognostic scores; biomarkers.


Cite This Article

Celik E, Samanci N, Karadag M, Demirci N, Demirelli F. Could Systemic İnflammation-Based Prognostic Scores Predict The Clinical Outcome in Patients with Breast Cancer Treated with Everolimus Plus Exemestane?. EJMI. 2021; 5(2): 225-231

Corresponding Author: Emir Celik

EJMI & EJMI